PE20110208A1 - Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno - Google Patents
Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indacenoInfo
- Publication number
- PE20110208A1 PE20110208A1 PE2011000041A PE2011000041A PE20110208A1 PE 20110208 A1 PE20110208 A1 PE 20110208A1 PE 2011000041 A PE2011000041 A PE 2011000041A PE 2011000041 A PE2011000041 A PE 2011000041A PE 20110208 A1 PE20110208 A1 PE 20110208A1
- Authority
- PE
- Peru
- Prior art keywords
- aza
- oxa
- dihydro
- compounds
- indacen
- Prior art date
Links
- VWPZCDAKAYFFLM-UHFFFAOYSA-N 2,6-dihydro-1h-furo[3,2-e]indole Chemical class O1CCC2=C1C=CC1=C2C=CN1 VWPZCDAKAYFFLM-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 102000001419 Melatonin receptor Human genes 0.000 abstract 1
- 108050009605 Melatonin receptor Proteins 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161485 | 2008-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110208A1 true PE20110208A1 (es) | 2011-03-28 |
Family
ID=41138660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000041A PE20110208A1 (es) | 2008-07-30 | 2009-07-29 | Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102219725B (zh) * | 2010-04-16 | 2013-10-09 | 中国科学院上海药物研究所 | 苯并杂环类化合物及其制备方法和用途 |
| AR091699A1 (es) | 2012-07-10 | 2015-02-25 | Astellas Pharma Inc | Derivado de indol carboxamida |
| CN104109143B (zh) * | 2013-04-22 | 2018-04-27 | 上海阳帆医药科技有限公司 | 一类褪黑激素(mt1-mt2)受体激动剂及其制备方法与用途 |
| CN104326916B (zh) * | 2014-10-10 | 2017-09-22 | 青岛农业大学 | 2‑氟‑4‑烯丙基‑6‑硝基苯酚与2‑氟‑4‑硝基‑6‑烯丙基苯酚的联合制备及用途 |
| US10640496B2 (en) * | 2016-06-17 | 2020-05-05 | Daewoong Pharmaceutical Co., Ltd. | Method for producing diphenylmethane derivative |
| CN118696029A (zh) * | 2021-12-24 | 2024-09-24 | 普赛洛私人有限公司 | 化合物 |
| KR20240044190A (ko) * | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 결정형 및 이의 제조방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600723A (en) | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| DE3466215D1 (en) | 1983-05-18 | 1987-10-22 | Univ Monash | The use of melatonin for the manufacture of a medicament |
| AU616907B2 (en) | 1987-08-17 | 1991-11-14 | Whitby Research, Inc. | Melatonin analogues |
| FR2680366B1 (fr) | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| EP0837850B1 (en) | 1995-06-27 | 2004-09-01 | Takeda Chemical Industries, Ltd. | 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists |
| US5732360A (en) | 1995-09-08 | 1998-03-24 | At & T Wireless Services And Atmel Corp | Mobile telecommunication device and method used for changing wireless communication between base stations of different kinds |
| CN100443480C (zh) | 1996-03-08 | 2008-12-17 | 武田药品工业株式会社 | 三环化合物及其制备和用途 |
| US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| FR2771739B1 (fr) | 1997-11-28 | 2001-04-20 | Adir | Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2784375B1 (fr) | 1998-10-12 | 2000-11-24 | Adir | Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2793793B1 (fr) | 1999-05-19 | 2004-02-27 | Adir | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1214944B1 (en) | 1999-08-20 | 2009-09-23 | Takeda Pharmaceutical Company Limited | Composition for PERCUTANEOUS ABSORPTION with a compound having a melatonin receptor agonist activity |
| FR2799757B1 (fr) | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6737431B2 (en) | 2002-03-12 | 2004-05-18 | Bristol-Myers Squibb Company | Benzoxazole derivatives as novel melatonergic agents |
| MXPA04012834A (es) | 2002-06-21 | 2005-04-25 | Suven Life Sciences Ltd | Arilalquil indoles novedosos que tienen afinidad por el receptor de la serotonina, utiles como agentes terapeuticos, proceso para su preparacion y composiciones farmaceuticas que los contienen. |
| US6908931B2 (en) | 2003-04-10 | 2005-06-21 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists |
| WO2005062992A2 (en) | 2003-12-23 | 2005-07-14 | Abraxis Bioscience, Inc | Substituted melatonin derivatives, process for their preparation, and methods of use |
-
2009
- 2009-07-29 CN CN2009801300227A patent/CN102112480A/zh active Pending
- 2009-07-29 AU AU2009275918A patent/AU2009275918A1/en not_active Abandoned
- 2009-07-29 RU RU2011107443/04A patent/RU2011107443A/ru not_active Application Discontinuation
- 2009-07-29 US US13/056,492 patent/US8227501B2/en not_active Expired - Fee Related
- 2009-07-29 UY UY0001032016A patent/UY32016A/es unknown
- 2009-07-29 EP EP09781255A patent/EP2350088A1/en not_active Withdrawn
- 2009-07-29 PE PE2011000041A patent/PE20110208A1/es not_active Application Discontinuation
- 2009-07-29 JP JP2011520509A patent/JP2011529477A/ja not_active Abandoned
- 2009-07-29 CA CA2731405A patent/CA2731405A1/en not_active Abandoned
- 2009-07-29 KR KR1020117002324A patent/KR20110041495A/ko not_active Withdrawn
- 2009-07-29 AR ARP090102880A patent/AR075262A1/es unknown
- 2009-07-29 WO PCT/EP2009/059829 patent/WO2010012789A1/en not_active Ceased
- 2009-07-29 BR BRPI0916395A patent/BRPI0916395A2/pt not_active IP Right Cessation
- 2009-07-29 TW TW098125512A patent/TW201018695A/zh unknown
- 2009-07-29 MX MX2011001062A patent/MX2011001062A/es active IP Right Grant
-
2011
- 2011-01-28 CL CL2011000184A patent/CL2011000184A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY32016A (es) | 2010-01-29 |
| US8227501B2 (en) | 2012-07-24 |
| CN102112480A (zh) | 2011-06-29 |
| KR20110041495A (ko) | 2011-04-21 |
| RU2011107443A (ru) | 2012-09-10 |
| AR075262A1 (es) | 2011-03-23 |
| JP2011529477A (ja) | 2011-12-08 |
| CA2731405A1 (en) | 2010-02-04 |
| US20110144178A1 (en) | 2011-06-16 |
| BRPI0916395A2 (pt) | 2016-02-16 |
| EP2350088A1 (en) | 2011-08-03 |
| MX2011001062A (es) | 2011-03-24 |
| WO2010012789A1 (en) | 2010-02-04 |
| CL2011000184A1 (es) | 2011-09-16 |
| TW201018695A (en) | 2010-05-16 |
| AU2009275918A1 (en) | 2010-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110208A1 (es) | Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| PE20091623A1 (es) | DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA | |
| PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
| PE20090892A1 (es) | MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3 | |
| PE20061335A1 (es) | Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c | |
| PE20090815A1 (es) | Compuesto de amida | |
| AR066155A1 (es) | Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia | |
| PE20081505A1 (es) | Inhibidores de serina palmitoiltransferasa | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| PE20091901A1 (es) | Activadores de glucoquinasa | |
| PE20141943A1 (es) | Antagonistas de trpv4 | |
| PE20091431A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| PE20080065A1 (es) | Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1 | |
| PE20141361A1 (es) | Compuesto heterociclico dihidroxi aromatico | |
| PE20140868A1 (es) | Antagonistas trpm8 y su uso en tratamientos | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| AR060812A1 (es) | Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn | |
| PE20081851A1 (es) | Derivados de espiropiperidina-glicinamida | |
| CL2012000516A1 (es) | Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros. | |
| PE20090655A1 (es) | Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |